Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.
The immune modulator Pomalyst led to remission in two thirds of people with AIDS-related Kaposi sarcoma.
A mid-stage trial shows islatravir plus Pifeltro shows promise as two-drug HIV regimen.
New research sheds light on HIV among transgender men and women
HIV advocates discuss how lessons from pandemic vaccine development can help fight COVID-19.
People living with HIV are learning how to cope with a new pandemic.
For pregnant women with HIV, dolutegravir-based regimens are apparently safest.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
HIV itself doesn’t raise the risk of getting the new virus, but some HIV-positive people are prone to severe illness.
A new study found that 44% of Medicaid enrollees with HIV who stopped antiretroviral treatment did not restart therapy within 18 months.
Experts recommend having at least a 30-day supply.
The Food and Drug Administration declined approval of ViiV Healthcare’s injectable HIV regimen Cabenuva.
ViiV applies for FDA approval of HIV drug fostemsavir
Amid talk of “ending HIV,” we must also focus on those with the virus, says Anthony S. Fauci, MD.
April/May 2020 Survey
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.